Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gilead Science (GILD) Followers -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (503)	1/5/1998 10:18:00 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 961

Ah, they are hyping again Zanamivir! But who will follow them?... Zanamivir=follow me..croatian When they have puppy (GS1404) coming in front of them.:) >>Zanamivir Protects Against Otologic Manifestations Of Influenza Infection WESTPORT, Jan 05 (Reuters) - A multicenter team's investigation of the pathogenetic role of respiratory viruses in development of acute otitis media led to the recent discovery that the antiviral agent zanamivir reduces the risk of otologic manifestations of human influenza, and potentially otitis media. In a recent study, almost 100 adult volunteers were inoculated with an influenza A or B virus. The volunteers were randomized to intranasal zanamivir as prophylaxis or treatment, or to placebo. As prophylaxis, zanamivir reduced the incidence of middle ear pressure abnormalities, a risk factor for otitis media, from 61% to 15%. Although this protection was observed in patients inoculated with either A or B viruses, "...the level of protection was lower against influenza B illness than against influenza A," Dr. Frederick G. Hayden of the University of Virginia Health Sciences Center in Charlottesville and a multicenter team report. In patients who were allowed to become infected and then treated with zanamivir, the antiviral reduced the incidence of middle ear pressure from 73% to only 32%. The authors explain in the December issue of the Journal of Infectious Diseases that "...these findings indicate that antiviral interventions, and specifically the neuraminidase inhibitor zanamivir, that are effective in preventing or reducing experimental influenza illness, provide protection against the development of [middle ear pressure] abnormalities and symptoms." J Infect Dis 1997;176:1417-1422.<< mz